Klein,aber fein: Adeona Pharmaceuticals

gestern Kaufempfehlung für Adeona in THE STREET von Stockpickr

Das Ding ist im Moment der Hit!

http://www.thestreet.com/_nasdaq/story/11338224/1/...ee&cm_ite=na  

für AEN gewesen.
Sogar jetzt im Plus,obwohl alles andere,vor allem auch Pharma, runtergeht.
Sehr gutes Zeichen!  

Anfang bis Mitte Dez. hat ca.1,10 gehalten und somit wurde SKS verhindert.
Könnte jetzt wieder Ri. 1,45 laufen.
Good Luck  

1,57 

Hoch 1,60

 

mit durchschnittlichem Gewinn von 70 % bei 1,69 raus.
Good Luck an alle noch investierten.  

Glückwunsch zu Adeona euch beiden und allen anderen,läuft im moment echt perfekt,und keiner weiss warum,es gibt ja bald eine Namens und fokussierungsänderung ! Was ich euch sagen wollte,speziell dir Heiko,wo du jetzt investieren kannst ist Schaut euch mal Lpath inc. (LPTN.OB) an,Hammerteil ! alles weitere zu Lpath in meinem neuen Thread .....

Bis bald !

MFG
Chali  

Tach Ihr zwei,

wir sind ja scheinbar die einzigen hier. Der Aufwärtstrend scheint mir ok, deswegen hab ich gestern auch die 1,88 mitgenommen und hoffe auf weiterhin Gutes.  

Danke Chali,
werd mir das mit LPTN mal überlegen.
CLDX gehen ja auch ganz gut,wie ich vermutete.

Grüße  

Leute

Adeona Begins Phase II Trial Of Trimesta For Cognitive Dysfunction In MS

(RTTNews.com) - Adeona Pharmaceuticals, Inc. (AEN) announced the initiation of the Phase II clinical trial of Trimesta (oral estriol) for treating cognitive dysfunction in multiple sclerosis, or MS.

The new Phase II clinical trial is a randomized, double-blind, placebo-controlled trial intended to enroll 64 relapsing-remitting or secondary-progressive female MS patients. Subjects will be equally randomized to receive either once-daily Trimesta or matching placebo. The primary outcome measure is the average change in PASAT scores at 12 months between each group. Secondary outcome measures include relapse rates, whole brain atrophy determined by MRI and safety.

Dr. Voskuhl, Principal Investigator, said, "We are very excited to initiate patient enrollment in this novel clinical trial of Trimesta in which the primary endpoint is improvement in cognition. Statistics show that 50-65 percent of patients affected by MS will develop disabilities due to a reduction in their cognitive processing speed. Despite the fact that cognitive dysfunction is a primary source of work related disability in MS, there remains no treatment to target this disability. The goal of this trial is to address this unmet need for MS patients, potentially improving a person's mental sharpness and ability to continue working."

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com




Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis


ANN ARBOR, Mich., Jan. 19, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today the initiation of the Phase II clinical trial of Trimesta™(oral estriol) for the treatment of cognitive dysfunction in multiple sclerosis (MS). This clinical trial is intended to enroll 64 relapsing-remitting or secondary-progressive female MS patients at University of California, Los Angeles (UCLA) and is being conducted at by Principal Investigator, Rhonda Voskuhl, M.D., Director, UCLA Multiple Sclerosis Program, Department of Neurology. There is currently no approved therapy for the treatment of cognitive dysfunction in MS.

"We are very excited to initiate patient enrollment in this novel clinical trial of Trimesta in which the primary endpoint is improvement in cognition. Statistics show that 50-65 percent of patients affected by MS will develop disabilities due to a reduction in their cognitive processing speed. Despite the fact that cognitive dysfunction is a primary source of work related disability in MS, there remains no treatment to target this disability," said Dr. Voskuhl, Principal Investigator. "The goal of this trial is to address this unmet need for MS patients, potentially improving a person's mental sharpness and ability to continue working."

This randomized, double-blind, placebo-controlled Phase II clinical trial is based on findings from a previously completed 10-patient, single-agent, crossover Phase I/II clinical trial conducted by Dr. Voskuhl and colleagues at UCLA. The results from the Phase I/II trial demonstrated a statistically significant 14% improvement from baseline in Paced Auditory Serial Addition Test (PASAT) cognitive testing scores in relapsing-remitting MS patients after six months of Trimesta™ therapy (p = 0.04). The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability and is widely used in MS to measure cognitive function. Estriol has also been shown to have neuroprotective benefits in animal models of MS, a property not generally shared by currently approved MS therapies.[ii]

The new Phase II clinical trial is a randomized, double-blind, placebo-controlled trial intended to enroll 64 relapsing-remitting or secondary-progressive female MS patients. Subjects will be equally randomized to receive either once-daily Trimesta™ (oral estriol) or matching placebo. The primary outcome measure is the average change in PASAT scores at 12 months between each group. Secondary outcome measures include relapse rates (the primary endpoint of the ongoing Phase II clinical trial of Trimesta™ for relapsing-remitting MS), whole brain atrophy determined by MRI and safety. Charitable organizations have pledged to financially support a majority of the new MS clinical trial. Detailed information regarding this clinical trial, including contact information for the clinical site, is available at http://www.clinicaltrials.gov/ct2/show/NCT01466114.

In addition to the clinical trial of Trimesta for cognitive dysfunction in MS, Trimesta™ is also the subject of a separate ongoing 15-center Phase II, randomized, double-blind, placebo-controlled clinical trial seeking to demonstrate Trimesta's ability to reduce relapse rates in women with the relapsing-remitting form of MS. With over $8 million in grant funding awarded to date, this separate ongoing Trimesta™ clinical trial should be funded to its completion. Additional information regarding the relapsing-remitting multiple sclerosis clinical trial is available at http://www.clinicaltrials.gov/ct2/show/NCT00451204.

"While our Board of Directors has strategically implemented several actions to prioritize our focus on the emerging field of synthetic biologics, our continued commitment to this important new MS clinical trial, having substantial external funding, is consistent with our mission of maintaining and building value for our shareholders," stated Jeffrey Riley, Adeona's Chairman of the Board.

About Trimesta™ (oral estriol)

Trimesta™ is Adeona's proprietary drug candidate for the treatment of relapsing-remitting MS and for cognitive dysfunction in MS, both in female patients. Estriol has been approved and marketed for more than 40 years throughout Europe and Asia for the treatment of post-menopausal symptoms. It has never been approved in the United States by the Food and Drug Administration (FDA) for any indication.

About Cognitive Dysfunction in Multiple Sclerosis

According to the National Multiple Sclerosis Society and the Multiple Sclerosis Society of Canada publication, Hold that Thought! Cognition and MS, it is fairly common for people with multiple sclerosis to complain of problems remembering things, finding the right words, concentrating on a task or something they are reading, or following a conversation. These are all cognitive symptoms of multiple sclerosis. Fifty to sixty-five percent of those affected by multiple sclerosis have cognitive dysfunction. Despite the fact that most symptoms are mild to moderate, they can have a significant impact on a person's ability to normally function. The overall cognitive dysfunction can be described as a reduction in mental "sharpness."

The major areas of cognition that can be dysfunctional include what are termed complex attention and executive functions. Complex attention involves multitasking, the speed with which information can be processed, learning and memory, and perceptual skills; executive functionsinclude problem solving, organizational skills, the ability to plan, and word finding. Just as the nature, frequency, and severity of multiple sclerosis-related physical problems can widely vary, not all people with multiple sclerosis will display these cognitive issues, and no two people will experience exactly the same types or severity of problems.


In December 2011, Adeona announced that the Board of Directors had taken several actions to prioritize the company's focus on its recent entry into the emerging field of synthetic biologics. As a result of its new primary focus, the Board approved a proposed name change of the company to Synthetic Biologics, Inc., to better reflect its new mission and primary business. Such name change is subject to stockholder approval.

Synthetic Biologics is a trademark of Adeona Pharmaceuticals, Inc.


For further information, please contact Adeona at (734) 332-7800, Ext. 22.

Sicotte, Liva, Klutch, Pfeiffer, Bouvier, Odesa, Wu, Voskuhl, Treatment of multiple sclerosis with the pregnancy hormone estriol, Ann Neurol. 2002 Oct;52(4):421-8.

[ii] Gold and Voskuhl, Estrogen treatment in multiple sclerosis, J Neurol Sci. 2009 Nov 15;286(1-2):99-103. Epub 2009 Jun 18.

SOURCE Adeona Pharmaceuticals, Inc.  

 

...schmeißt einer 15.300 Shares. F...ck! After Hours 2,04. Aber ich denke, AEN macht ihren Weg.  

Hey leute,Adeona scheint grundlos heissgelaufen,es bietet sich eine erstklassige chance in die weitaus interessantere Astex umzuschichten,die heute sogar noch mal 22% billiger geworden ist ich habe einen Thread zu Astex aufgemacht !

Adeona Pharmaceuticals

My only concern for Adeona is knowing that the recent run was accompanied by modest company news, and after watching Adeona run, fall, and now running again, I'm left to wonder: Is this real? Or is this just deep pockets taking advantage of a good situation? I don't mean to sound pessimistic, but more than one quality firm has been hurt by the Market's unexplainable 'run' then 'dump', especially in the age of computer flash-crashes. Or for excited long-investors who finally see their investment going up and wake up the next morning to read that the company is diluting shares or selling equity securities but this of course is due to the company's new direction with Intrexon Corporation.

I am scratching my head over Adeona, but its pps movement demands careful attention. Up big, down big, and now up big to $2.10/share on Friday's close. Someone is making a lot of money. But here again, like Astex, no conclusive reason unless you are bullish on the stock and think it is sorely under-valued.

What I especially like is when I see a penny-land biotech improving itself and that's my interpretation of the Intrexon deal along with the impending new name signifying the new direction for Adeona. Existence is futile unless biotechs take active steps to stay one step ahead

Astex Pharmaceuticals

Among SA authors, I am a small minority who see the value in former SuperGen, now Astex. But it doesn't matter. Astex is on fire because the share price has jumped from $1.51/share on 30 November 2011 to Friday's close at $2.72/share. That is a monstrous jump in a very short two months.

As my #2 Top 3 Biotech picks, Astex is still under-valued at $2.72/share. I realize few biotechs go straight up, and retracing and accumulation may occur, but I wouldn't be surprised if Astex goes over $3/share as it hit $3.27/share on 2 June 2011. I will be more surprised if Astex doesn't go over $4/share in the coming months.

With a supplementary new drug application FDA decision ahead for Dacogen, investors are probably seeing the pps recovery and run-up going into the news. There will always be day-traders who will claim their lion's-share, but back in 2011, I observed that Astex may be a great trading stock with its variable ups and downs. Or for long-traders, sitting tight, and holding. Clearly, when it hit $1.51/share, that was a gift and congratulations to anyone who jumped in at a fabulous moment.

Still, the Market is hard to interpret and what happens after Friday's run won't be know until Monday. Yet it goes without saying that Astex is cash-flush, so I'm inclined to think the Market is returning the value to Astex that it should have been all along.

MFG
Chali